As of November 6, 2026, Neurocrine Biosciences Inc is a publicly traded company (Nasdaq: NBIX); its largest reported holder is Vanguard, with 5.23% on Schedule 13G of April 30, 2026, then JPMorgan Chase (5.2%). The largest insider holding is Gorman Kevin Charles, a director, with 517,797 shares (0.51% of shares outstanding), per Form 4 of September 15, 2026 (Schedule 13G, April 30, 2026).
Is this your company?
About to sign with, pay or invest in Neurocrine Biosciences Inc? See the free Snapshot first.
Free to see. No signup.
Is Neurocrine Biosciences Inc a real, registered company?
- Neurocrine Biosciences Inc files with the SEC under CIK 914475 (its SEC filings).
- Its shares are listed under the ticker NBIX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in San Diego, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Neurocrine Biosciences Inc in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Eiry W. Roberts, Chief Medical Officer (Form 8-K filed 2026-09-28). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Vanguard (filed 2026-10-30).
Who are Neurocrine Biosciences Inc's owners and officers?
Neurocrine Biosciences Inc: incorporated in Delaware; business address in San Diego, California; industry Biological Products, (No Diagnostic Substances) (Schedule 13G, 2026-10-30).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-30 | Vanguard Portfolio Management | 5% |
| Schedule 13G/A, 2026-10-15 | Jpmorgan Chase & Co. | 5.2% |
| Schedule 13G/A, 2026-07-27 | Jpmorgan Chase & Co. | 6.3% |
| Schedule 13G, 2026-04-30 | Vanguard Capital Management | 5.23% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G, 2026-01-21 | Jpmorgan Chase & Co. | 5.2% |
Questions about who owns Neurocrine Biosciences Inc
Who owns Neurocrine Biosciences Inc?
On this page, 3 holders' latest ownership filings report 5% or more of Neurocrine Biosciences Inc: Vanguard Capital Management (5.23%, Schedule 13G, filed 2026-04-30), Jpmorgan Chase & Co. (5.2%, Schedule 13G/A, filed 2026-10-15) and Vanguard Portfolio Management (5%, Schedule 13G, filed 2026-10-30).
Who are the largest shareholders of Neurocrine Biosciences Inc?
By the share each holder's latest filing reports, the largest holders of Neurocrine Biosciences Inc on this page are Vanguard Capital Management (5.23%), Jpmorgan Chase & Co. (5.2%) and Vanguard Portfolio Management (5%).
When did Vanguard Capital Management buy into Neurocrine Biosciences Inc?
The filings give report dates, not purchase dates. The earliest filing from Vanguard Capital Management on this page is the Schedule 13G, filed 2026-04-30, reporting 5.23%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Neurocrine Biosciences Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Neurocrine Biosciences Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Neurocrine Biosciences Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-09-28 | Eiry W. Roberts | Chief Medical Officer | appointed | 2026-09-28 |
Which insiders own Neurocrine Biosciences Inc shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 517,797 shares (0.51% of shares outstanding) (Form 4, 2026-09-15).
- , the chief executive and a director: 155,010 shares (0.15% of shares outstanding) (Form 4, 2026-11-03).
- , a director: 122,141 shares (0.12% of shares outstanding) (Form 4, 2026-05-21).
- , the chief commercial officer: 67,297 shares (0.07% of shares outstanding) (Form 4, 2026-09-15).
- , the chief legal officer: 56,793 shares (0.06% of shares outstanding) (Form 4, 2026-09-15).
Shares outstanding: 101,218,643 as of 2026-10-26, from the company's latest SEC cover page.
How much has Neurocrine Biosciences Inc raised?
Acquisitions reported on Form 8-K, Item 2.01: acquired Soleno Therapeutics, Inc. (2026-05-18).
Keep reading
More on Neurocrine Biosciences Inc and the records around it.
Neurocrine Biosciences Inc elsewhere on the record
- Leadership changes Sep 2026
Companies that share a holder
- JPMORGAN CHASE & CO. also filed stake reports on 116 other companies: LEVI STRAUSS & CO (Nov 2026), Warner Music Group Corp. (Nov 2026), Andersen Group Inc. (Oct 2026)
- Vanguard Portfolio Management also filed stake reports on 941 other companies: Newmark Group Inc (Nov 2026), A10 Networks Inc (Oct 2026), ADT Inc (Oct 2026)
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/neurocrine-biosciences